Key insights
- Eli Lilly EVP Ilya Yuffa sold $2.88 million in stock via a pre-arranged plan, occurring as LLY trades near its 52-week high. While this insider selling might raise minor concerns, the company also received FDA approval for a new dosing regimen for Ebglyss and reported promising Phase 3 trial results for its obesity drug Retatrutide, leading analysts to maintain Outperform/Buy ratings. The positive drug development news largely offsets the insider transaction's potential negative signal.
Ilya Yuffa, Executive Vice President and President of LLY USA & Global Capabilities at Eli Lilly & Co (NYSE:LLY), sold 2,500 shares of the company’s common stock on June 10, 2026. The transaction totaled $2,876,925, with shares sold at a price of $1150.77 each.
The sale was executed pursuant to a Rule 10b5-1 trading plan, which Mr. Yuffa adopted on February 13, 2026. The transaction comes as Eli Lilly shares trade near their 52-week high of $1,182.73, with the stock delivering a strong 44% return over the past year. Following this transaction, Mr. Yuffa directly holds 29,804.111 shares of Eli Lilly common stock.According to InvestingPro analysis, the pharmaceutical giant currently appears overvalued relative to its Fair Value. Investors seeking deeper insights can access 16 additional ProTips and comprehensive financial metrics on the platform, including detailed Pro Research Reports available for LLY and over 1,400 US equities.
In other recent news, Eli Lilly received approval from the U.S. Food and Drug Administration for a new dosing regimen of its drug Ebglyss. This allows patients with moderate-to-severe atopic dermatitis to receive an injection every eight weeks, reducing the number of annual maintenance doses to six. Previously, the drug required monthly injections. Meanwhile, Eli Lilly’s obesity and diabetes drug, Retatrutide, has shown promising results in recent Phase 3 trials. The TRIUMPH-1 trial demonstrated a 17% weight loss with a 4mg dose and approximately 30% with a 12mg dose, while maintaining a discontinuation rate similar to placebo. Following these results, Bernstein reiterated an Outperform rating on Eli Lilly, highlighting the drug’s potential impact. Similarly, Truist Securities maintained a Buy rating, noting the drug’s best-in-class weight loss efficacy. These developments suggest Eli Lilly is solidifying its position in the obesity and type 2 diabetes market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Most traders can read a chart. The hard part is the moment: entry window open, pattern forming, and you're still waiting for more confirmation. That's the conviction gap — and our chart analysis closes it. Unlike other AIs that just read data, our Vision AI literally "sees" your charts and hands you a complete trading plan: entry, stop-loss, and profit target in under 60 seconds. Know exactly what to do next, every time.